10,13-dimethyl-17-[1-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]propan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 10,13-dimethyl-17-[1-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]propan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• 化学式: C28H38N4O4
• 分子量: 494.6
• InChiKey: DLWLXTLRGQWGPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Probiotic strains having cholesterol absorbing capacity, methods and uses thereof
  申请人：BIOSEARCH, S.A.

  公开号：US11058734B2

  公开（公告）日：2021-07-13

  The invention relates to a probiotic strain selected from Lactobacillus reuteri V340 with accession number CECT and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity, and to methods and therapeutic uses thereof. The invention also relates to compositions, pharmaceutical compositions, feeds or nutritional products comprising a probiotic strain selected from Lactobacillus reuteri V3401 with accession number CECT 8605 and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity.

  本发明涉及一种益生菌株，该益生菌株选自登录号为CECT的克氏乳杆菌V340和登录号为CECT 8606的乳双歧杆菌BT820，或具有胆固醇吸收能力的上述益生菌株的变体，以及其方法和治疗用途。本发明还涉及一种组合物、药物组合物、饲料或营养产品，其中包含一种益生菌株，该益生菌株选自登录号为 CECT 8605 的 Lactobacillus reuteri V3401 和登录号为 CECT 8606 的 Bifidobacterium breve BT820，或具有胆固醇吸收能力的所述益生菌株的变体。
• PROBIOTIC STRAINS HAVING CHOLESTEROL ABSORBING CAPACITY, METHODS AND USES THEREOF
  申请人：BIOSEARCH, S.A.

  公开号：US20170333495A1

  公开（公告）日：2017-11-23

  The invention relates to a probiotic strain selected from Lactobacillus reuteri V340 with accession number CECT and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity, and to methods and therapeutic uses thereof. The invention also relates to compositions, pharmaceutical compositions, feeds or nutritional products comprising a probiotic strain selected from Lactobacillus reuteri V3401 with accession number CECT 8605 and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity.